Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) EPS (Basic) (2022 - 2025)

Historic EPS (Basic) for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to -$0.37.

  • Zentalis Pharmaceuticals' EPS (Basic) rose 3392.86% to -$0.37 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.07, marking a year-over-year increase of 1686.75%. This contributed to the annual value of -$2.33 for FY2024, which is 4779.58% up from last year.
  • Zentalis Pharmaceuticals' EPS (Basic) amounted to -$0.37 in Q3 2025, which was up 3392.86% from -$0.37 recorded in Q2 2025.
  • In the past 5 years, Zentalis Pharmaceuticals' EPS (Basic) registered a high of $0.14 during Q1 2024, and its lowest value of -$1.85 during Q2 2023.
  • In the last 4 years, Zentalis Pharmaceuticals' EPS (Basic) had a median value of -$0.83 in 2023 and averaged -$0.85.
  • In the last 5 years, Zentalis Pharmaceuticals' EPS (Basic) skyrocketed by 11308.41% in 2024 and then tumbled by 57857.14% in 2025.
  • Zentalis Pharmaceuticals' EPS (Basic) (Quarter) stood at -$0.92 in 2022, then grew by 9.78% to -$0.83 in 2023, then rose by 19.53% to -$0.67 in 2024, then soared by 44.6% to -$0.37 in 2025.
  • Its last three reported values are -$0.37 in Q3 2025, -$0.37 for Q2 2025, and -$0.67 during Q1 2025.